Targeted next generation sequencing of MLH1 ‐deficient, MLH1 promoter hypermethylated, and BRAF / RAS ‐wild‐type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions

Abstract excerpt

Oncogenic gene fusions represent attractive targets for therapy of cancer. However, the frequency of actionable genomic rearrangements in colorectal cancer (CRC) is very low, and universal screening for these alterations seems to be impractical and costly. To address this problem, several large scale studies retrospectivelly showed that CRC with gene fusions are highly enriched in groups of tumors defined by MLH1...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Colorectal Cancer Treatments and Studies